Thomas-Christian Mix
Corporate Officer/Principal at DYNE THERAPEUTICS, INC.
Profile
Thomas-Christian Mix's current job is Senior Vice President-Pharmacovigilance at Dyne Therapeutics, Inc. Dr. Mix's former jobs include being a Medical Director-Global Development at Amgen, Inc. from 2003 to 2015, an Executive Director-Global Medical Sciences at Alexion Pharmaceuticals, Inc. from 2015 to 2017, a Vice President-Clinical Development at Sarepta Therapeutics, Inc. from 2017 to 2018, and a Vice President-Clinical Development at Agios Pharmaceuticals, Inc. from 2018 to 2019.
Dr. Mix's education includes an undergraduate degree from Haverford College in 1989, a graduate degree from UMass Chan Medical School in 1995, and a graduate degree from Sackler School of Graduate Biomedical Sciences in 2003.
Thomas-Christian Mix active positions
| Companies | Position | Start |
|---|---|---|
| DYNE THERAPEUTICS, INC. | Corporate Officer/Principal | 2020-01-31 |
Former positions of Thomas-Christian Mix
| Companies | Position | End |
|---|---|---|
| AGIOS PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2019-09-30 |
| SAREPTA THERAPEUTICS, INC. | Corporate Officer/Principal | 2018-04-30 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2017-04-30 |
| AMGEN INC. | Corporate Officer/Principal | 2014-12-31 |
Training of Thomas-Christian Mix
| Haverford College | Undergraduate Degree |
| UMass Chan Medical School | Graduate Degree |
| Sackler School of Graduate Biomedical Sciences | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| DYNE THERAPEUTICS, INC. | Health Technology |
| AGIOS PHARMACEUTICALS, INC. | Health Technology |
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Private companies | 1 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Thomas-Christian Mix
